A Phase 2 clinical trial evaluating oxytocin has been marked as terminated, according to a ClinicalTrials.gov update dated August 28, 2026. The study, registered under identifier NCT04427709, was titled "Generate and Test the Reliability of a PD Model of OXT on Pupillary Hippus as a Measure of CNS Activity."
The trial was designed to generate and test a pharmacodynamic model examining oxytocin's relationship to pupillary hippus, a measure being explored as an indicator of central nervous system activity. The study status is listed as terminated in the Phase 2 category.
The available record does not provide a stated reason for termination, nor does it include any efficacy or safety results. No outcome data, adverse event information, or conclusions about oxytocin's effects on pupillary hippus or CNS activity have been disclosed in connection with this status update.
Oxytocin remains an approved compound, and this update pertains specifically to the status of this individual investigational trial rather than to its approved uses. Readers should note that a termination status reflects a change in trial conduct and does not by itself indicate any finding about the compound's safety or effectiveness.
Those interested in learning more about oxytocin's background and approved status can consult the compound overview for additional context.